IMPACC Links Acute COVID-19 to Viral Reactivation

Key Takeaways

• Among hospitalized patients with COVID-19, acute illness was accompanied by significant Herpesviridae and Anelloviridae reactivation.
• Viral reactivation correlated with disease severity, host immune effects, and clinical outcomes in the cohort.
• Viral reactivation persisted into convalescence, and convalescent Anelloviridae transcripts were associated with a physical-deficit long-COVID phenotype; acute-phase reactivation was not significantly associated with the study's long-COVID outcome groups.

Many people hospitalized with COVID-19 carry chronic viruses that can re-emerge during severe illness. With SARS-CoV-2 infection, reactivation may accompany systemic inflammation and recovery, but it's unclear whether it's a marker of illness, part of the host response, or both. Investigators examined that question in the Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC).

A longitudinal multi-omic analysis within IMPACC followed 1,154 hospitalized patients with COVID-19 through acute illness and convalescence. Investigators reported significant reactivation of Herpesviridae and Anelloviridae during acute COVID-19. Different viruses showed distinct temporal dynamics rather than a single shared pattern, and the study also reported immune, transcriptomic, and metabolomic signatures accompanying reactivation.

Viral reactivation also correlated with disease severity, host immune effects, and clinical outcomes. The authors wrote that chronic viral reactivation occurred frequently in immunocompetent individuals during severe illness and alongside increased systemic inflammation. Reactivation remained detectable in convalescence, and convalescent Anelloviridae transcripts were associated with a physical-deficit long-COVID phenotype; acute-phase reactivation was not significantly associated with the study's long-COVID outcome groups.

These results do not establish causation between viral reactivation and clinical outcomes.

Clinician Questions

Did viral reactivation cause worse COVID-19 outcomes or long COVID in the IMPACC cohort?

No. Investigators reported correlations with disease severity, host immune effects, clinical outcomes, and an association between convalescent Anelloviridae transcripts and a physical-deficit long-COVID phenotype; acute-phase reactivation was not significantly associated with the study's long-COVID outcome groups, and the authors explicitly said the results do not establish causation.

What host-response signals accompanied viral reactivation in the IMPACC COVID-19 analysis?

The investigators reported immune, transcriptomic, and metabolomic signatures of viral reactivation in hospitalized COVID-19 patients.